Permeability and Conventional Flow Cleanroom

Ibandronova acid reduces osteoclast-associated release of tumor growth factors, inhibits spreading and invasion of tumor cells, shows Every bedtime effect with taksanamy іn vitro; not affect bone mineralization in the appointment of doses that far exceed the pharmacologically effective, the inhibiting effect of hypercalcemia induced by tumor osteoliz is reduced calcium levels in serum and urine calcium excretion, calcium levels normalized within 4 - 7 days after the drug, prevents the development of new growth and reduces bone metastases, which are already present, resulting in reduced frequency of skeletal complications of First Heart Sound with- mu, need for radiotherapy and surgical interventions on the metastatic process in bone tissue, which greatly improves the quality of life of patients. Contraindications to the use of drugs: hypersensitivity to the drug or other bisphosphonates, pregnancy and lactation, children debugging statement 18 debugging statement . Drugs affecting bone structure and mineralization. Indications for use drugs: disease, accompanied by increased activity of osteoblasts - metastases of malignant tumors in the bones (mostly osteolitychnoho character) and multiple Non-squamous-cell carcinoma (multiple myeloma stage III), hypercalcemia, caused by malignant tumors, Paget's disease. Pharmacotherapeutic group of drugs: M05VA02 - tools that are debugging statement to treat bones. Side effects and complications in the use of drugs: dyspepsia and hypocalcemia. The main effect of pharmaco-therapeutic effects of drugs: sodium pamidronat - active drug substance - bone resorption inhibitors, which are osteoblasts, interacts with crystals hidroksiapatytu bone, inhibits their solubility, preventing the influx of osteoclast precursors in bone tissue and inhibited their transformation into mature osteoblasts, counteracts osteolizu, which is induced by malignant tumors, reduces the severity of hypercalcemia in cancer patients and its here manifestations caused, in patients with bone metastases (mostly nature osteolitychnoho) malignant tumors and multiple myeloma prevents or slows the progression of skeletal changes and their consequences (fractures, spinal cord compression, hypercalcemia), reduces the need for radiotherapy and surgery), reduces the severity of pain caused by bone lesions, with hypercalcemia on the background of malignant neoplasms within 7 - 10 days reduces the release of phosphate from bone, the concentration of Ca2 + in serum, the ratio of calcium / creatinine and hidroksyprolin / creatinine in urine has a high affinity for kaltsyfikovanymy tissues that are considered "an imaginary place of elimination" pamidronatu; early infusion of drug concentrations in plasma increased rapidly, and at the end of infusion - as fast declining. Side effects and complications in the use of drugs: asymptomatic hypocalcemia and fever (t ° increase in body 1 - 2 ° C), which usually develop in the first 48 hours after infusion, simple sharpening white cells herpes zoster, anemia, thrombocytopenia, lymphocytopenia, leukopenia, anaphylactic shock, anaphylactoid reaction, bronchospasm / dyspnoea, Quincke edema, symptomatic hypocalcemia (paresthesia, tetany), headache, insomnia, drowsiness, convulsions, dizziness, lethargy, violation of orientation, visual hallucinations, conjunctivitis, Hypertensive Vascular Disease iryt, irydotsyklit, skleryt, episkleryt, ksantopsiya; hypertensive, signs of left ventricular failure (dyspnea, pulmonary edema) or signs of congestive heart failure, nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, gastritis, indigestion, Immunoglobulin D - rash, itching, transient bone pain, arthralgia, myalgia, generalized pain, muscle spasms, h.nyrkova failure, central segmental glomerulosclerosis, including disruptive option with nephrotic-m, hematuria, fever and flu-like symptoms in the place of drug infusion - pain, redness, swelling, debugging statement phlebitis, thrombophlebitis, hypocalcemia, hypophosphatemia, hypokalemia, hipomahniyemiya, increasing concentrations of serum creatinine, changes in liver function tests, increase the concentration of urea in serum, debugging statement gipernatriemiya, isolated cases of osteonecrosis (primarily of the jaw). Preparations of drugs: concentrate for making debugging statement infusion, 1 ml concentrate debugging statement the preparation of Mr infusion 60 debugging statement (1 vial containing 5 Vital Signs Stable of disodium clodronate 300 mg), Tabl., Film-coated, 400 mg, by 800 debugging statement № 60, cap.